Intravesical Gem/Doce in Patients With NMIBC

Inclusion Criteria

• •1. Patients able to consent in English or Spanish; provision of signed and dated informed consent form
• •2. Stated willingness to comply with all study procedures and availability for the duration of the study
• •3. Male or female ages ≥18 years.
• •4. Patients with intermediate or high-risk non-muscle-invasive UC of the bladder and no previous BCG treatment.
• •1. Histologically confirmed intermediate or high-risk non-muscle invasive urothelial carcinoma of the bladder (Ta, T1, or Tis stage) on Transurethral Resection of Bladder Tumor (TURBT) must be obtained within 180 days of registration. OR Patients with a high-grade recurrence after 24 months since last dose of BCG.
• •6\. Eastern Cooperative Oncology Group (ECOG) performance status Grade 0-2. 7. Post-transurethral bladder tumor resection. 8. Evidence of post-menopausal status or negative urinary pregnancy test of female pre-menopausal patients is required. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.